Survival analyses of the ZeOxaNMulti trial: Follow-up randomized, double-blinded, placebo-controlled trial of oral PMA-zeolite to prevent chemotherapy-induced side effects, especially peripheral neuropathy.

Furthermore, PFS analysis indicated that there was a borderline significant difference between the study groups when the time of PMA-ZEO usage was evaluated ( p = 0,05).

also in 11,409 other papers

A longer OS was observed in elderly patients (age>70 years) and first-line chemotherapy pts in the PMA-ZEO group (median time of OS = 39.7 months, CI = 3.1–76.3) in comparison with the placebo group (median time of OS = 21.8 months, CI = 15.2–28.3); the difference was marginally significant ( p = 0.06).

also in 26,082 other papers

A positive trend and more importantly, significant results in PFS and OS for specific patient groups during and/or after PMA-ZEO treatment were determined, which supports the use of PMA-ZEO as an oncological supportive therapy. oxaliplatin PMA-zeolite chemotherapy-induced peripheral neuropathy colorectal cancer dis

also in 11,005 other papers